Enanta Pharmaceuticals (ENTA) Deferred Taxes (2014 - 2020)

Enanta Pharmaceuticals (ENTA) has 7 years of Deferred Taxes data on file, last reported at $15.0 million in Q3 2020.

• Quarterly Deferred Taxes rose 1363.63% year-over-year to $15.0 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $10.6 million (up 438.05% YoY) and the FY2021 annual result came in at $345000.0, down 96.75% from the prior year.
• Deferred Taxes rose to $15.0 million in Q3 2020, from -$3.1 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $15.0 million in Q3 2020 to a low of -$3.8 million in Q2 2017.
• A 5-year average of $263052.6 and a median of -$918000.0 in 2018 frame the typical range for Deferred Taxes.
• Annual changes were most pronounced in 2016 — Deferred Taxes sank 5816.67% — and 2020, when it soared 1363.63%.
• Tracing ENTA's Deferred Taxes over 5 years: stood at -$1.9 million in 2016, then surged by 239.37% to $2.7 million in 2017, then plunged by 134.49% to -$918000.0 in 2018, then surged by 171.57% to $657000.0 in 2019, then soared by 2179.15% to $15.0 million in 2020.
• The last three Deferred Taxes figures came in at $15.0 million (Q3 2020), -$3.1 million (Q2 2020), and -$1.9 million (Q1 2020), per Business Quant data.